Phase 0–IV Clinical Trial: Guidelines for Chinese Patients
Clinical Trials & Advanced Therapies
Clinical trials are grouped into phases, and the phase tells you what the study is designed to answer. Confusing a phase I safety study with a phase III comparison is the single most common misunderstanding among patients searching for trials abroad.
What each phase answers
- Phase 0 — microdose studies in a very small number of patients, asking whether a drug reaches its target. Not a treatment.
- Phase I — safety, tolerability and dosing, usually in patients who have exhausted standard options; response is monitored but not the primary question.
- Phase II — activity in a defined tumour type or population, often single-arm.
- Phase III — comparison against the current standard, randomised, and the basis for approval.
- Phase IV — post-approval surveillance for rare or long-term effects.
How to read a trial record
Look at the phase, the status (recruiting, not yet recruiting, active but not recruiting), the comparator arm, the primary endpoint and the number of participants. A phase II single-arm study can offer access to a promising drug, but it cannot tell you whether that drug is better than standard care. That distinction should shape the decision.
Matching the phase to the situation
Patients with a good standard option usually should not trade it for a phase I study. Patients who have exhausted standard options may reasonably consider phase I or II, accepting greater uncertainty. Phase III participation is often the most clinically informative choice when eligibility allows, because the comparison is real.
Questions to ask the investigator
- What is the primary endpoint, and when will results be analysed?
- If I am randomised to the comparator, what treatment will I receive?
- Can I cross over, and under what conditions?
- What happens if the trial is stopped early?
Next step: send us the trial registration numbers you are considering and we will explain, in plain terms, what each study can and cannot answer for your case.
